Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Agilon Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the securities of Agilon Health, Inc. is from February 26, 2025, to August 4, 2025 [1]. - Investors who purchased Agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 2, 2026 [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements and failed to disclose critical information, including that they issued guidance for 2025 that was unlikely to be achieved due to known industry challenges [5]. - It is claimed that the defendants overstated the immediate financial benefits from strategic actions taken by Agilon to mitigate risks, leading to materially false statements about the company's business and prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Agilon Health, Inc. related to shareholder interests [1] Group 1: Allegations of Misrepresentation - A federal securities lawsuit claims that insiders at Agilon Health misrepresented or failed to disclose critical information, including that the 2025 guidance was issued recklessly, knowing it was unattainable [2] - The lawsuit also alleges that the positive financial impact from strategic actions taken by Agilon to mitigate risk was materially overstated [2] - Consequently, statements regarding the company's business, operations, and prospects were materially false and/or misleading during relevant periods [2] Group 2: Shareholder Participation - Shareholders who purchased Agilon Health stock prior to February 26, 2025, are encouraged to contact Kuehn Law, which covers all case costs and does not charge its clients [3] - The firm emphasizes the importance of shareholder involvement in maintaining the integrity and fairness of financial markets [4]

Core Viewpoint - Agilon Health, Inc. is facing a class action lawsuit due to significant stock price decline following the announcement of leadership changes and poor financial results, which allegedly stemmed from misleading statements made by the company's executives [2][3]. Group 1: Company Events - On August 4, 2025, Agilon announced the departure of its President, CEO, and Director, which was classified as a termination without cause [2]. - The company released its second quarter 2025 financial results on the same day, missing estimates and suspending its 2025 guidance due to leadership changes and market uncertainties [2]. - Following this news, Agilon's stock price dropped by $0.93, or 51.5%, closing at $0.88 per share on August 5, 2025 [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that Agilon's executives made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specifically, it is claimed that the executives recklessly issued guidance for 2025 that they knew was unattainable due to known industry challenges [3]. - Additionally, the complaint states that the executives overstated the immediate financial benefits from strategic actions taken to mitigate risks, rendering their positive statements misleading [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][5]. Group 1: Allegations Against Agilon Health - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [5]. - It is claimed that the company overstated the financial benefits from strategic actions taken to mitigate risks, leading to materially false representations about its business and prospects [5]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% the next day, indicating significant investor losses [6]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased agilon health securities between February 26, 2025, and August 4, 2025, are encouraged to discuss their legal rights and options, with a deadline of March 2, 2026, to seek the role of lead plaintiff in the class action [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [7]. - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct [8].

Group 1 - The article highlights the upcoming deadline of March 2, 2026, for investors to file a lead plaintiff motion in a case related to agilon health, inc. (NYSE: AGL) [1] - The case involves investors who purchased agilon health securities during the class period from February 26, 2025, to August 4, 2025 [1] - The law offices of Howard G. Smith are encouraging investors who suffered losses in agilon health to participate in the ongoing case [1]

Core Viewpoint - The Gross Law Firm is notifying shareholders of agilon health, inc. regarding a class action lawsuit due to alleged misleading statements and guidance issued by the company during the specified class period [1][2]. Group 1: Allegations - The complaint alleges that agilon health, inc. issued materially false and/or misleading statements during the class period from February 26, 2025, to August 4, 2025 [1]. - It is claimed that the defendants recklessly provided guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [1]. - The complaint also states that the defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risk, leading to materially false and misleading statements about the company's business and prospects [1]. Group 2: Class Action Details - Shareholders who purchased shares of AGL during the class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for March 2, 2026 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Agilon Health, Inc. regarding a class action lawsuit due to alleged misleading statements and guidance issued by the company during a specified period [1][3]. Group 1: Allegations - The complaint alleges that Agilon Health's defendants issued materially false and/or misleading statements and failed to disclose critical information during the class period from February 26, 2025, to August 4, 2025 [3]. - Specific allegations include that the defendants recklessly provided guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - Additionally, it is claimed that the defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risk, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Class Action Details - Shareholders who purchased shares of Agilon Health during the class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for March 2, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [5].

Core Viewpoint - A securities fraud lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) following a significant drop in its stock price after the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Agilon Health's shares fell over 25% in after-hours trading on August 4, 2025, due to the unexpected resignation of CEO Steven Sell and the withdrawal of the company's full-year 2025 financial guidance [2]. - The company cited unexpected medical cost pressures and downward adjustments to prior revenue estimates as reasons for these actions [2]. Group 2: Legal Allegations - The lawsuit alleges that Agilon Health recklessly issued guidance for 2025 that was unlikely to be achieved, given known industry challenges [3]. - It is claimed that Agilon materially overstated the financial benefits from strategic actions intended to mitigate risks, leading to misleading statements about its business and prospects [3]. Group 3: Investor Information - Investors who purchased Agilon Health common stock between February 26, 2025, and August 4, 2025, may be eligible to recover losses, regardless of whether they sold their shares [4]. - The deadline to seek appointment as lead plaintiff in the lawsuit is March 2, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about Agilon Health are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Legal Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding its financial guidance and business operations during the Class Period from February 26, 2025, to August 4, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants issued guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - It is alleged that defendants overstated the immediate financial benefits from strategic actions taken to mitigate risks [3]. - As a result, statements made about Agilon's business, operations, and future prospects were materially false and misleading throughout the Class Period [3]. Next Steps - Investors who purchased Agilon shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 2, 2026 [7].

Core Viewpoint - A securities fraud class action lawsuit has been filed against agilon health, inc. on behalf of investors who acquired its securities during the specified Class Period, following significant stock price decline due to leadership changes and missed financial estimates [1][2]. Group 1: Company Developments - On August 4, 2025, agilon announced the departure of its President, CEO, and Director, which was classified as a termination without cause under his employment agreement [2]. - The company released its second quarter 2025 financial results on the same day, which missed estimates and led to the suspension of its 2025 guidance due to leadership changes and ongoing market uncertainties [2]. Group 2: Stock Performance - Following the announcement of leadership changes and poor financial results, agilon's stock price dropped by $0.93, or 51.5%, closing at $0.88 per share on August 5, 2025 [2]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, agilon's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include that management issued guidance for 2025 that was known or should have been known to be unachievable due to industry headwinds, and that they overstated the financial impact of strategic actions taken to reduce risk [3].